New diagnostic and therapeutic tools
against multidrug resistant tumours

Scientific publications

Please, add the following sentence for any scientific publication related to the STRATAGEM COST Action:

This work was performed within the framework of COST Action CA17104 STRATAGEM -” New diagnostic and therapeutic tools against multidrug resistant tumors”.

After publication of a contribution related to the Stratagem COST Action please send the citation as formatted in the first paper to stratagem.cost@gmail.com

  1. Mohr T, Katz S, Paulitschke V, Aizarani N, Tolios A. Systematic Analysis of the Transcriptome Profiles and Co-Expression Networks of Tumour Endothelial Cells Identifies Several Tumour-Associated Modules and Potential Therapeutic Targets in Hepatocellular Carcinoma. Cancers. 202113, 1768. https://doi.org/10.3390/cancers13081768
  2. Kivrak A, Ulaş B, Kivrak H. A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2. International Immunopharmacology. 2021, 90, doi: 10.1016/j.intimp.2020.107232
  3. Vasconcelos M H, Alcaro S, Arechavala-Gomeza V, Baumbach J, Borges F, Brevini T A L , De Las Rivas J, Devaux Y, Hozak P, Keinänen-Toivola M M, Giovanna Lattanzi G, Mohr T, Murovska M, Prusty B K, Quinlan R A, Pérez-Sala D, Scheibenbogen C, Schmidt H H W, Silveira I, Tieri P, Tolios A, Riganti C. Joining European Scientific Forces to Face Pandemics. Trends in Microbiology. 2020, doi: 10.1016/j.tim.2020.10.008
  4. Hurtová M, Biedermann D, Kuzma M, Křen V. Mild and Selective Method of Bromination of Flavonoids. Journal of Natural Products. 2020, 83 (11), 3324. doi: 10.1021/acs.jnatprod.0c00655
  5. Viktorová J, Kumar R, Řehořová K, Hoang L, Ruml T, Figueroa CR, Valdenegro M, Fuentes L. Antimicrobial Activity of Extracts of Two Native Fruits of Chile: Arrayan (Luma apiculata) and Peumo (Cryptocarya alba). Antibiotics. 2020, 9(8), 444. doi: 10.3390/antibiotics9080444
  6. Viktorová J, Stupák M, Řehořová K, Dobiasová S, Hoang L, Hajšlová J, Thanh TV, Tri LV, Tuan NV, Ruml T. Lemon Grass Essential Oil Does not Modulate Cancer Cells Multidrug Resistance by Citral—Its Dominant and Strongly Antimicrobial Compound. Foods. 2020, 9(5), 585. doi: 10.3390/foods9050585
  7. Tran VN, Viktorova J, Augustynkova K, Jelenova N, Dobiasova S, Rehorova K, Fenclova M, Stranska-Zachariasova M, Vitek L, Hajslova J, Ruml T. In Silico and In Vitro Studies of Mycotoxins and Their Cocktails; Their Toxicity and Its Mitigation by Silibinin Pre-Treatment. Toxins. 2020, 12(3), 148. doi: 10.3390/toxins12030148
  8. Dobiasová S, Řehořová K, Kučerová D, Biedermann D, Káňová K, Petrásková L, Koucká K, Václavíková R, Valentová K, Ruml T, Macek T. Multidrug Resistance Modulation Activity of Silybin Derivatives and Their Anti-Inflammatory Potential. Antioxidants. 2020, 9(5), 455. doi: 10.3390/antiox9050455
  9. Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resistance Updates 2020, 53, 100715. doi: 10.1016/j.drup.2020.100715
  10. Durante M, Frosini M, Fusi F, Gamberucci A, Chegaev K, Rolando B, Riganti C, Fruttero R, Saponara S. In vitro vascular toxicity assessment of NitDOX, a novel NO-releasing doxorubicin. European Journal of Pharmacology 2020, 880, 173164. doi: 10.1016/j.ejphar.2020.173164
  11. Palmeira A, Sousa E, Köseler A, Sabirli R, Gören T, Türkçüer İ, Kurt Ö, Pinto M, Vasconcelos MH. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection. Pharmaceuticals 2020, 13(6), 132; doi: 10.3390/ph13060132
  12. Dinić J, Efferth T, Garcia-Sosa A, Grahovac J, Padrón J, Pajeva I, Rizzolio F, Saponara S, Spengler G, Tsakovska I. Repurposing old drugs to fight multidrug resistant cancers. Drug Resistance Updates 2020, , 100713. doi: 10.1016/j.drup.2020.100713
  13. Lepeltier E, Rijo P, Rizzolio F, Popovtzer R, Petrikaite V, Assaraf YG, Passirani C. Nanomedicine to Target Multidrug Resistant Tumors. Drug Resistance Updates 2020, 52, 100704. doi: 10.1016/j.drup.2020.100704
  14. Isca V, Sencanski M, Filipovic N, Dos Santos D, Čipak Gašparović A, Saraíva L, Afonso C, Rijo P, García-Sosa A. Activity to Breast Cancer Cell Lines of Different Malignancy and Predicted Interaction with Protein Kinase C Isoforms of Royleanones. International Journal of Molecular Sciences 2020, 21, 3671. doi: 10.3390/ijms21103671
  15. Isca V, Ferreira R, Garcia C, Monteiro C, Dinic J, Holmstedt S, André V, Pešić M, Dos Santos D, Candeias N, Afonso C, Rijo P. Molecular Docking Studies of Royleanone Diterpenoids from Plectranthus spp. as P-Glycoprotein Inhibitors. ACS Medicinal Chemistry Letters 2020, 11, 839-845. doi: 10.1021/acsmedchemlett.9b00642
  16. Stark M, Silva, TFD, Levin G, Machuqueiro M, Assaraf YG. The Lysosomotropic Activity of Hydrophobic Weak Base Drugs is Mediated via Their Intercalation into the Lysosomal Membrane. Cells 2020, 9, 1082. doi: 10.3390/cells9051082
  17. Fathy Abd-Ellatef GE, Gazzano E, Chirio D, Hamed AR, Belisario DC, Zuddas C, Peira E, Rolando B, Kopecka J, Assem Said Marie M, Sapino S, Ramadan Fahmy S, Gallarate M, Abdel-Hamid AZ, Riganti C. Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells. Pharmaceutics. 2020, 12, E96. doi: 10.3390/pharmaceutics12020096
  18. Dallavalle S, Dobričić V, Lazzarato L, Gazzano E, Machuqueiro M, Pajeva I, Tsakovska I, Zidar N, Fruttero R. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resistance Updates 2020, 50, 100682. doi: 10.1016/j.drup.2020.100682
  19. Kopecka J, Trouillas P, Gašparović AČ, Gazzano E, Assaraf YG, Riganti C. Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. Drug Resistance Updates 2020, 49, 100670. doi: 10.1016/j.drup.2019.100670
  20. Tolios A, De Las Rivas J, Hovig E, Trouillas P, Scorilas A, Mohr T. Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions. Drug Resistance Updates 2020, 48, 100662. doi: 10.1016/j.drup.2019.100662
  21. Andrei L, Kasas S, Ochoa Garrido I, Stanković T, Korsnes MS, Vaclavikovak R, Assaraf YG, Pešić M. Advanced technological tools to study multidrug resistance in cancer. Drug Resistance Updates 2020, 48, 100658. doi: 10.1016/j.drup.2019.100658
  22. Dömötör O, Kiss MA, Gál GT, May NV, Spengler G, Nové M, Gašparović AČ, Frank É, Enyedy ÉA. Solution equilibrium, structural and cytotoxicity studies on Ru(η(6)-p-cymene) and copper complexes of pyrazolyl thiosemicarbazones. Journal of Inorganic Biochemistry 2020, 202, 110883. doi: 10.1016/j.jinorgbio.2019.110883.
  23. Dinić J, Ríos-Luci C, Karpaviciene I, Cikotiene I, Fernandes MX, Pešić M, Padrón JM. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells. Investigational New Drugs 2020, 38, 584-598. doi: 10.1007/s10637-019-00803-6
  24. Vasconcelos MH, Caires HR, Ābols A, Xavier CPR, Linē A. Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance. Drug Resistance Updates 201947, 100647. doi: 10.1016/j.drup.2019.100647
  25. Sarmento-Ribeiro AB, Scorilas A, Gonçalves AC, Efferth T, Trougakos IP. The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resistance Updates 201947, 100646. doi: 10.1016/j.drup.2019.100646
  26. Lazzarato L, Gazzano E, Blangetti M, Fraix A, Sodano F, Picone GM, Fruttero R, Gasco A, Riganti C, Sortino S. Combination of PDT and NOPDT with a Tailored BODIPY Derivative. Antioxidants 20198, E531. doi: 10.3390/antiox8110531
  27. Puerta A, Galán AR, Abdilla R, Demanuele K, Fernandes MX, Bosica G, Padrón JM. Naphthol-derived Betti bases as potential SLC6A14 blockers. Journal of Molecular and Clinical Medicine 2019, 2, 35-40. doi: 10.31083/j.jmcm.2019.02.7181
  28. Gazzano E, Kopecka J, Belisario CD, Costamagna C, Riganti C.  A new LDL-masked liposomal doxorubicin overcomes drug resistance in osteosarcoma. Journal of Molecular and Clinical Medicine 20192, 1-9. doi: 10.31083/j.jmcm.2019.01.6161
  29. Garcia C, Ntungwe E, Rebelo A, Bessa C, Stankovic T, Dinic J, Díaz-Lanza A, Reis CP, Roberto A, Pereira P, Cebola M-J, Saraiva L, Pešić M, Duarte N, Rijo P. Parvifloron D from Plectranthus strigosus: Cytotoxicity screening of Plectranthus spp. extracts. Biomolecules 2019, 9, 616. doi: 10.3390/biom9100616
  30. Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPE, Vasconcelos H. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resistance Updates 2019, 46, 100645. doi: 10.1016/j.drup.2019.100645
  31. Alexa-Stratulat T, Pešić M, Gašparović AČ, Trougakos IP, Riganti C. What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. Drug Resistance Updates 2019, 46, 100643. doi: 10.1016/j.drup.2019.100643
  32. Dinić J, Podolski-Renić A, Jovanović M, Musso L, Tsakovska I, Pajeva I, Dallavalle S, Pešić M. Novel Heat Shock Protein 90 inhibitors suppress P-glycoprotein activity and overcome multidrug resistance in cancer cells. International Journal of Molecular Sciences 201920, 4575. doi: 10.3390/ijms20184575.
  33. Viktorová J, Dobiasová S, Řehořová K, Biedermann D, Káňová  K, Šeborová K, Václavíková R, Valentová K, Ruml T, Křen V, Macek T. Antioxidant, anti-inflammatory, and multidrug resistance modulation activity of silychristin derivatives. Antioxidants 2019, 8, 303. doi: 10.3390/antiox8080303
  34. Podolski-Renić A, Dinić J, Stanković T, Jovanović M, Ramović A, Pustenko A, Žalubovskis R, Pešić M. Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance. European Journal of Pharmaceutical Sciences 2019, 138, 105012. doi: 10.1016/j.ejps.2019.105012
  35. Rodrigues C, Milković L, Tartaro Bujak I, Tomljanović M, Soveral G, Gašparović AČ. Lipid profile and aquaporin expression under oxidative stress in breast cancer cells of different malignancies. Oxidative Medicine and Cellular Longevity 2019, 2019, 2061830. doi: 10.1155/2019/2061830
  36. Gazzano E, Kopecka J, Castella B, Buondonno I, Costamagna C, Riganti C. Novel anthracyclines with enhanced immunogenic effects against drug resistant osteosarcoma cells. Journal of Molecular and Clinical Medicine 2018, 1, 227-236. doi: 10.31083/j.jmcm.2018.04.325001